Comparison of Ciprofol, Remimazolam, and Propofol on Arrhythmia Inducibility in Pediatric Supraventricular Tachycardia: A Retrospective Study

环丙酚、瑞米唑仑和丙泊酚对儿童室上性心动过速诱发心律失常的比较:一项回顾性研究

阅读:1

Abstract

PURPOSE: Propofol is a commonly used intravenous anesthetic in pediatric patients. Ciprofol and remimazolam, newly approved agents, cause minimal injection pain and demonstrate stable hemodynamic characteristics. This study aimed to evaluate their effects on arrhythmia inducibility in pediatric supraventricular tachycardia (SVT). PATIENTS AND METHODS: A retrospective analysis was conducted on the clinical data of pediatric patients with supraventricular tachycardia who underwent radiofrequency ablation under general anesthesia from May 2020 to June 2024. After excluding 28 cases, 173 patients were deemed eligible for analysis. According to the intravenous anesthesia drugs administered, the patients were classified into the propofol group (Group P), the ciprofol group (Group C), and the remimazolam group (Group R). The primary outcome measure was the arrhythmia inducibility, while the secondary outcome measures encompassed ablation success, extubation time, bispectral index (BIS) value, peri - operative relevant parameters, and the incidence of postoperative nausea and vomiting. RESULTS: No significant difference was observed in the arrhythmia inducibility among the three groups (97.40% vs 95.35% vs 94.34%) (P>0.05). The secondary outcome measures in the three groups, including ablation success (P > 0.05), isoprenaline use (P > 0.05), recurrence (P > 0.05) and operation time (P > 0.05), were similar. Additionally, there was no significant difference in the incidence rates of nausea and vomiting. Excluding the baseline BIS, the Bispectral Index values of Group R were significantly higher than those of Group P and Group C at the same time point (P<0.05). Moreover, the extubation time in Group R was shorter than that in Group P and Group C. CONCLUSION: The effects of ciprofol and remimazolam on arrhythmia inducibility in pediatric supraventricular tachycardia were comparable to those of propofol. Both ciprofol and remimazolam are appropriate for radiofrequency ablation of supraventricular tachycardia in pediatric patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。